HOME >> MEDICINE >> NEWS
Cell Pathways' Aptosyn™ (exisulind) shows continuing long-term prevention of colon polyps in FAP patients

Results of Phase III Trial and Extension Study Data Presented by Cleveland Clinic Investigator at American Gastroenterological Association Meeting

Clinical results from familial adenomatous polyposis (FAP) patients treated with Aptosyn™(exisulind) for up to 18 months were presented today at the annual meeting of the American Gastroenterological Association (AGA) by Carol Burke, M.D. of the Cleveland Clinic Foundation. Results of a one year double-blinded, placebo-controlled Phase III trial and its six month open-label extension, sponsored by Cell Pathways, Inc. (Nasdaq: CLPA), demonstrate that Aptosyn™ induces a clinically significant reduction in the formation of precancerous colon polyps in patients with FAP after as little as six months of therapy. Moreover, patients who have continued on Aptosyn™ for more than one year continue to show further improvement over time.

In a separate release the company announced the presentation of preclinical research being presented at AGA showing that colonic tumor cells marked by hereditary defects different from the APC gene mutation that characterizes FAP also undergo apoptosis, or programmed cell death, when treated with Aptosyn. The company also reported laboratory findings that the cyclic GMP phosphodiesterase targeted by Aptosyn™ and other selective apoptotic antineoplastic drugs (SAANDs) is over-expressed in colonic neoplasias relative to normal colonic mucosal tissue. This observation may explain in part the selectivity of SAANDs for precancerous and cancerous cells and not for normal tissue.

Results of Phase III Trial and Extension Study

"Based on the clinical responses that we have observed to date, use of exisulind for the chemoprevention of colonic adenomas has the potential to significantly alter the management of patients with FAP," commented Dr. Burke, a principal investigator for the Phase III study and for the previous Phase II trial of Aptosyn&
'"/>

Contact: Joan Kureczka, J. Kureczka Assoc.
JKureczka@aol.com
415-821-2413
Kureczka/Martin Associates
22-May-2000


Page: 1 2

Related medicine news :

1. Study shows promise in identifying kidney failure
2. Study shows patch therapy may be as effective as oral medications
3. Study shows soy is well accepted in school lunches
4. Chronic pain treatments more effective when taken together, new study shows
5. UW study shows blacks and Latinos are more satisfied with physicians of the same race
6. Vaccine against childhood pneumonia shows promise
7. UW research shows risk factors for relapse among health care professionals who abuse drugs
8. Study shows use of budesonide reduced the risk of asthma related events by 40% in children
9. New technique shows promise for improved straightening of crooked nose
10. Chemical decoy shows promise for slowing Alzheimers by acting as decoy
11. Study shows risk of cardiac death after radiation for breast cancer has dramatically decreased

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/4/2020)... (PRWEB) , ... June 04, 2020 , ... ... and substance abuse treatment services has announced the addition of the Illness Management ... integrated into the larger treatment curriculum at each facility to provide programming that ...
(Date:6/2/2020)... ... 02, 2020 , ... RemetricHealth , a leading remote ... industry for more than a decade, announced today the launch of its new ... 2010, RemetricHealth, then known as PMD Healthcare, developed the first-ever patented, FDA-approved at-home ...
(Date:5/30/2020)... , ... May 29, 2020 , ... In appreciation for ... more than ever, James Hodge Hyundai is offering a $500 bonus towards the lease ... of this incentive now through January 4, 2021. , To qualify for this offer, ...
(Date:5/28/2020)... (PRWEB) , ... May 28, 2020 , ... ... to fully re-open in the fall, operators of student housing are scrambling to ... return. COCM, which manages over 37,000 student housing beds on 38 campuses across ...
(Date:5/27/2020)... (PRWEB) , ... May 27, ... ... 2020 , Guest: Dr. Gerald Pollack, University of Washington Professor of Bioengineering, ... of Water: Beyond Solid, Liquid & Vapor ( https://www.amazon.com/Fourth-Phase-Water-Beyond-Liquid-ebook/dp/B00N2ASKF2 ) , ...
Breaking Medicine News(10 mins):
(Date:5/30/2020)... (PRWEB) , ... May 29, 2020 , ... ... following statement in response to the U.S. announcement that it will terminate its ... the Administration’s announcement that it plans to terminate its relationship with the World ...
(Date:5/28/2020)... ... 28, 2020 , ... Deborah Heart and Lung Center, New ... the Cleveland Clinic Heart, Vascular & Thoracic Institute, has announced the introduction of ... COPD is a growing and devastating disease and is the third leading cause ...
(Date:5/27/2020)... ... ... reviewed and approved in April 2020: , CARDIOLOGY, Passaic County, Dr. Anuj Shah ... Dr. Mansoo Jo , Dr. Mi Jo , Morris County, ... Dr. Jeffrey Rapaport , FAMILY PRACTICE, Camden County, Dr. Krista ...
Breaking Medicine Technology:
Cached News: